GOSS (gossamerbio.com) Market Value to Book Value Ratio

Official company branding of Gossamer Bio Inc (GOSS)

The price indicator on the Gossamer Bio, Inc. (GOSS) chart reflects the dynamics of a company developing immune-boosting agents. The current figure stands at -0.60. The business relies on external investments, as the trial stage precludes a regular inflow of funds. Meanwhile, an ecological approach in the laboratories is combined with the scalability of the pulmonary hypertension treatment project, which minimizes costs through the support of a strategic partner.

GOSS Gossamer Bio Corp.: Market Value to Book Value in the range 07/04/2022 - 10/27/2026
Original product of Gossamer Corp

To filter for high-quality assets, investors utilize the price-to-book ratio, which determines the premium or discount of the market price relative to net assets. This metric assesses the financial stability of Gossamer Bio, Inc. (GOSS), reflecting the extent to which the market overvalues the resources deployed in joint clinical trials with medical centers, as clearly demonstrated by the historical trend of the price-to-book multiple.

Main competitors

argenx SE - Market Value to Book Value Ratio|BNTX (biontech.de) - Market Capitalization to Book Value|Market Value to Book Value Ratio abivax.com ABVX|Market Capitalization to Net Assets ADMA Biologics Inc|Protagonist Therapeutics Inc (PTGX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Immunovant Therapeutics (IMVT)|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|grifols.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Adaptive Biotechnologies Corporation (ADPT)|CLDX: Market Value to Book Value|AUPH (Aurinia Pharma) - Market Value to Book Value Ratio|BioCryst Corp (BCRX) - Market Cap to Net Assets Ratio|VERA (Vera Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio dianthustx.com (DNTH)|Pharvaris (PHVS) - Market Cap to Net Assets Ratio|Market Value to Book Value AbCellera Biologics (ABCL)|Market Capitalization to Book Value Ratio TRML|Precigen Corp - Market Capitalization to Book Value|PHAR: Market Value to Book Value Ratio|NKTR: Market Cap to Net Assets Ratio|UPB (Upstream Bio) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Zenas Bio|IMNM (Immunome Corp) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio KALV|Market Value to Book Value Ratio Septerna Inc SEPN|Capitalization to Book Value Ratio pieris.com (PVLA)|SVRA: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Rigel Pharma RIGL|Market Capitalization to Book Value Ratio ANAB|ATXS: Market Value to Equity Ratio|Market Value to Book Value Ratio ENGN|RAPT (rapt.com) - Market-to-Book Ratio|JBIO: Market Value to Book Value Ratio|Market Capitalization to Book Value ACRS|KYTX (Kyverna) - Market Value to Book Value Ratio|Market Capitalization to Book Value Tiziana Life Sciences, Ltd. (TLSA)|Market Capitalization to Book Value Ratio CABA (Cabaletta Bio, Inc.)|ventyxbio.com - Market Capitalization to Book Value Ratio|THTX: Market Value to Book Value Ratio|AVTX - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio ELDN|AGEN (Agenus, Inc) - Market-to-Book Ratio|CLYM - Market Value to Book Value Ratio|Market Value to Book Value zurabio.com (ZURA)|aTyr Pharma (ATYR) - Market Cap to Net Assets Ratio|Market Value to Book Value adagene.com (ADAG)|Market Capitalization to Book Value Ratio Ikena Oncology IMA|Market Value to Book Value Ratio Shattuck Labs Inc STTK|Market Capitalization to Book Value Ratio EQ (Equillium Bio)|CNTB: Market Capitalization to Book Value|Market Value to Book Value Ratio IMUX|Market-to-Book Ratio Atara Bio|IFRX - Market Cap to Net Assets Ratio|Market Value to Book Value X4 Pharmaceuticals, Inc|ACET (Adicet Bio) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value CELU (celularity.com)|INMB - Market Value to Book Value Ratio|Capitalization to Book Value Ratio Barinthus Biotherapeutics PLC BRNS|KZR: Market Capitalization to Book Value Ratio|SAB Biotherapeutics Inc (SABS) - Market Cap to Net Assets Ratio|Akari Therapeutics - Market Cap to Net Assets Ratio|Enlivex Therapeutics Ltd. (ENLV) - Market Capitalization to Book Value|Q32 Bio Inc - Market Capitalization to Book Value Ratio|Market Value to Equity Ratio GOVX|Edesa - Market Value to Book Value Ratio|Market-to-Book Ratio IBIO (iBio Corporation)|Market Value to Book Value Ratio CARM|xtlbio.com - Market Capitalization to Book Value|Market Value to Book Value Ratio BOLT (Bolt Bio)|HCWB: Market Capitalization to Book Value|Market Value to Book Value Ratio aptevotherapeutics.com (APVO)|aimimmuno.com (AIM) - Market Capitalization to Net Assets|ADTX - Market Capitalization to Book Value Ratio|Market Value to Book Value gribio.com|Market Capitalization to Book Value Ratio XRTX|Market Capitalization to Book Value Ratio HIND (Vyome Holdings Inc.)|Market Value to Book Value Ratio Revelation Bio|Indaptus Corp - Market Value to Book Value|SCNI: Market Value to Book Value Ratio|CALI - Market Cap to Net Assets Ratio|AFMD: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Allakos|HOOK - Market Cap to Net Assets Ratio|Market Value to Book Value IGM Bio|ITOS (iTeos Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value OCEA (oceanbiomedical.com)|TC BioPharm - Market Value to Book Value Ratio|Third Harmonic Bio Inc. - Market Cap to Net Assets Ratio